Chandra Vargeese
About Chandra Vargeese
Chandra Vargeese serves as the Chief Technology Officer and Head of Platform Discovery Sciences at Wave Life Sciences, where he has worked since 2014. He has a notable background in nucleic acid delivery technologies and has co-invented Macugen, an FDA-approved drug for Age Related Macular Degeneration.
Current Role at Wave Life Sciences
Chandra Vargeese serves as the Chief Technology Officer and Head of Platform Discovery Sciences at Wave Life Sciences. He has held this position since 2014, contributing to the company's focus on nucleic acid-based therapeutics. His responsibilities include overseeing the development of innovative technologies for nucleic acid delivery and enhancing the platform's capabilities. Vargeese's leadership in this role is instrumental in advancing the company's research and development initiatives.
Previous Experience at Novartis
Prior to his current role, Chandra Vargeese worked at Novartis as Executive Director from 2008 to 2014. During his tenure in Cambridge, USA, he focused on the development of nucleic acid delivery technologies. His work included the invention of various delivery systems such as liposomes and polymers, which are essential for effective therapeutic applications.
Background in RNA Therapeutics
Chandra Vargeese has a strong background in RNA therapeutics, having led efforts in chemistry and delivery technologies. His work has been pivotal in the development of systems for the systemic delivery of nucleic acids to the liver and tumors. His expertise includes the optimization of chemistry to enhance nucleic acid stability and the design of novel constructs for targeted delivery.
Education and Academic Achievements
Chandra Vargeese earned his Doctor of Philosophy (PhD) from the Indian Institute of Science (IISc) between 1983 and 1988. He furthered his studies as a Post Doctoral Fellow at the University of Rhode Island from 1988 to 1992, where he focused on nucleoside antivirals. His academic background laid the foundation for his extensive research and contributions to the field of nucleic acid therapeutics.
Patents and Publications
Chandra Vargeese has a strong track record of patents and publications in the field of nucleic acid-based therapeutics. His contributions include co-inventing Macugen, an FDA-approved aptamer drug for Age Related Macular Degeneration (AMD). His work has significantly impacted the development of nucleic acid delivery technologies and therapeutic applications.